<DOC>
	<DOCNO>NCT02136511</DOCNO>
	<brief_summary>This study provide idelalisib ( IDELA ) individual relapse , previously treat chronic lymphocytic leukemia ( CLL ) limit treatment option eligible Gilead-sponsored study .</brief_summary>
	<brief_title>Expanded Access Idelalisib Combination With Rituximab Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Male female ≥ 18 year age diagnosis Bcell CLL establish accord International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) criterion document within medical record 2 . CLL warrant treatment ( consistent accept IWCLL criterion initiation therapy ) 3 . Prior treatment CLL comprise follow : 1 . Prior treatment ≥ 1 regimen contain therapeutic antiCD20 antibody 2 . Prior treatment ≥ 2 regimen contain ≥ 1 cytotoxic agent 4 . CLL progression &lt; 24 month since completion last prior therapy CLL 5 . Appropriate noncytotoxiccontaining therapy base presence follow factor : 1 . Grade ≥ 3 neutropenia thrombocytopenia attributable cumulative myelotoxicity prior administration cytotoxic agent ( document bone marrow biopsy obtain since last prior therapy ) , 2 . Estimated creatinine clearance &lt; 60 mL/min ( determine CockcroftGault method ) , 3 . A Cumulative Illness Rating Scale ( CIRS ) score &gt; 6 6 . A negative serum pregnancy test female subject childbearing potential 7 . Male female subject childbearing potential engage heterosexual intercourse must agree use protocolspecified method ( ) contraception . 8 . Lactating female must agree discontinue nursing study drug administer . 9 . Evidence personally sign informed consent 1 . Known hypersensitivity idelalisib , metabolite , formulation excipient ( ) 2 . Known histological transformation CLL aggressive lymphoma ( ie , Richter transformation ) 3 . Known myelodysplastic syndrome 4 . Evidence ongoing systemic bacterial , fungal , viral infection time randomization 5 . Ongoing druginduced liver injury , chronic active hepatitis C ( HCV ) , chronic active hepatitis B ( HBV ) , alcoholic liver disease , nonalcoholic steatohepatitis , primary biliary cirrhosis , extrahepatic obstruction cause cholelithiasis , cirrhosis liver , portal hypertension 6 . Ongoing druginduced pneumonitis 7 . Ongoing inflammatory bowel disease 8 . History anaphylaxis association previous administration monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>